Neulasta® (pegfilgrastim) – New NDC

A new administration option for Neulasta® is now available: the Neulasta® Delivery Kit.

The Neulasta® Delivery Kit (NDC: 55513-192-01) requires administration by a healthcare provider and is available at the same WAC (wholesale acquisition cost) as the currently available Neulasta® prefilled syringe (NDC:  55513-190-01).

Neulasta® is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Please click here for the Neulasta® Prescribing Information.

Please click here for the On-body Injector for Neulasta® Instructions for Use.

No comments have been posted yet.